

## DISCLOSURE INFORMATION

## Research Presentations Financial Disclosure Statements

The International Society for Pharmacoeconomics and Outcomes Research asked all abstract contributors to disclose financial support for their research. The following financial support was declared:

REFERENCE CODE	FINANCIAL SUPPORT	REFERENCE CODE	FINANCIAL SUPPORT
CN1	None	PCN37	None
CN2	Nucletron bv, Veenendaal, The Netherlands	PCN38	Janssen Pharmaceuticals, Inc., Raritan, NJ, USA
CN3	CTMM, Eindhoven, The Netherlands	PCN39	Roche Farmacêutica Quimica, Amadora, Portugal
CN4	Bristol Myers Squibb, Uxbridge, UK	PCN40	Janssen Pharmaceuticals, Inc., Raritan, NJ, USA
CP1	Genzyme, Naarden, The Netherlands; BioMarin, Dublin, Ireland	PCN41	Sanofi-Aventis, Warsaw, Poland
CP2	None	PCN42	Bayer Healthcare Pharmaceuticals, Inc., Wayne, NJ, USA
CP3	The Cochrane Collaboration, Oxford, UK	PCN43	None
CP4	None	PCN44	Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
CV1	Novartis, Basel, Switzerland	PCN45	None
CV2	Amgen, Inc., Thousand Oaks, CA, USA	PCN46	Janssen, Sao Paulo, Brazil
CV3	Novartis Pharma B.V., Arnhem, The Netherlands	PCN47	Meda Pharma, Frankfurt, Germany
CV4	Roche Products Ltd., Welwyn Garden City, UK	PCN48	Pfizer, Mexico, Mexico
DI1	None	PCN49	None
DI2	National Institute of Health, Bethesda, MD, USA	PCN50	None
DI3	Abbott Diabetes Care, ROME, Italy	PCN51	None
DI4	Instituto de Salud Carlos III PFIS-11 FIS ISCIII (320), Madrid, Spain; DIUE, Generalitat de Catalunya (2009 SGR 1095), Barcelona, Spain; Instituto de Salud Carlos III FEDER PI13/00506, Madrid, Spain	PCN52	None
HC1	None	PCN53	Eisai, Woodcliff Lakes, NJ, USA
HC2	Decision Resources Group, Burlington, MA, USA	PCN54	Green Cross, Yong-In, South Korea
HC3	LIF, Stockholm, Sweden; National Center for Priority Setting in Health Care, Linköping, Sweden	PCN55	Pfizer, Inc., São Paulo, Brazil
HC4	ICON, London, UK	PCN56	Genomic Health, Geneva, Switzerland
HS1	Janssen, Beerse, Belgium	PCN58	GlaxoSmithKline d.o.o., družba za promet s farmacevtskimi izdelki, Ljubljana, Slovenia, Ljubljana, Slovenia
HS2	None	PCN59	KWF Cancer Research, Amsterdam, The Netherlands
HS3	None	PCN60	Teva Pharmaceutical, Philadelphia, PA, USA
HS4	None	PCN61	National Cancer Institute, Boulogne Billancourt, France
MA1	The Netherlands Organisation for Health Research and Development (ZonMW), The Hague, The Netherlands	PCN62	French National Cancer Institute, Boulogne Billancourt, France
MA2	Kantar Health, Epsom, UK	PCN63	Roche Products Limited, Welwyn Garden City, UK
MA3	None	PCN64	MSD Italy, Rome, Italy
MA4	None	PCN65	None
MO1	None	PCN66	None
MO2	Novartis Pharma AG, Basel, Switzerland	PCN67	None
MO3	Medical Research Council, Bristol, UK; Mapi, Houten, The Netherlands	PCN68	GlaxoSmithKline Slovakia s.r.o., Bratislava, Slovak Republic
MO4	None	PCN69	GlaxoSmithKline Biologicals S.A., Rixensart, Belgium
NI1	None	PCN70	Laboratórios Pfizer Lda, Lisbon, Portugal
NI2	None	PCN71	None
NI3	None	PCN72	Pfizer, Mexico, Mexico
NI4	None	PCN73	None
PCN1	Eisai Inc., Woodcliff Lake, NJ, USA	PCN74	None
PCN2	None	PCN75	None
PCN4	None	PCN76	None
PCN5	Janssen Pharmaceuticals, Inc., Raritan, NJ, USA	PCN77	None
PCN6	Genentech, San Francisco, CA, USA	PCN78	None
PCN7	Bristol-Myers Squibb, Rueil-Malmaison, France	PCN79	Health Research Board, Dublin, Ireland
PCN8	Boehringer Ingelheim International, Ingelheim, Germany	PCN80	None
PCN9	Bristol-Myers Squibb, Plainsboro, NJ, USA	PCN81	2Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA
PCN10	Janssen Pharmaceuticals, Inc., Raritan, NJ, USA	PCN82	None
PCN11	F. Hoffmann - La Roche AG, Basel, Switzerland	PCN83	Sanofi Pasteur MSD, Maidenhead, UK
PCN12	Janssen, Beerse, Belgium	PCN84	Eisai, Woodcliff Lake, NJ, USA
PCN13	None	PCN85	Pfizer, New York, NY, USA
PCN14	Janssen Pharmaceuticals, Inc., Raritan, NJ, USA	PCN86	Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
PCN15	Sobi, Solna, Sweden	PCN87	UERJ, Rio de Janeiro, Brazil; UFF, Niterói, Brazil
PCN16	Merck Serono, Feltham, UK; Merck Serono, Darmstadt, UK	PCN88	Pfizer, Mexico, Mexico
PCN20	Eli Lilly and Company, Windlesham, UK	PCN89	The Ministry of Science and Education of the Republic of Serbia for Grant N°175014, Belgrade, Serbia and Montenegro
PCN21	Janssen-Cilag, Neuss, Germany	PCN90	Amgen Inc., Thousand Oaks, CA, USA
PCN22	National Institute of Health Research, London, UK	PCN91	None
PCN23	Janssen-Cilag, High Wycombe, UK	PCN92	None
PCN24	Janssen-Cilag BV, Tilburg, The Netherlands; Janssen-Cilag AB, Sollentuna, Sweden; Janssen-Cilag GMBH, Neuss, Germany	PCN93	Innovative Medicine Initiative, Brussels, Belgium
PCN25	Novartis, Basel, Switzerland	PCN94	Department of Health, Canberra, Australia
PCN26	Novartis, Moscow, Russia	PCN95	the Center for Translational Molecular Medicine, Eindhoven, The Netherlands
PCN27	Roche Farmacêutica Quimica, Amadora, Portugal	PCN96	None
PCN28	None	PCN97	Norgine Ltd., Uxbridge, UK
PCN29	GlaxoSmithKline, Zeist, The Netherlands	PCN98	GlaxoSmithKline S.R.L., Bucharest, Romania
PCN30	IPSEN, Boulogne-Billancourt, France	PCN99	None
PCN31	None	PCN100	Productos Roche, Bogota, Colombia
PCN32	None	PCN101	BMS Spain, Madrid, Spain
PCN33	Bristol-Myers Squibb, Rueil Malmaison, France	PCN102	None
PCN34	None	PCN103	Janssen, Panama, Panama
PCN35	None	PCN104	Novartis, Camberley, UK
PCN36	None	PCN105	Genesis Pharma, Athens, Greece
		PCN106	Amgen, Zug, Switzerland
		PCN107	GSK, Tres Cantos (Madrid), Spain

REFERENCE CODE	FINANCIAL SUPPORT	REFERENCE CODE	FINANCIAL SUPPORT
PCN108	AstraZeneca, Mexico City, Mexico	PCN188	None
PCN109	GlaxoSmithKline, Mississauga, ON, Canada	PCN189	None
PCN110	Amgen, Athens, Greece	PCN190	NIHR School for Primary Care Research, London, UK
PCN111	Amgen, Athens, Greece	PCN191	Astellas Pharma a/s, Kastrup, Denmark
PCN112	Roche Hungary, Budapest, Hungary	PCN192	None
PCN113	GlaxoSmithKline Biologicals S.A., Rixensart, Belgium	PCN193	None
PCN114	None	PCN194	Amgen (Europe) GmbH, Zug, Switzerland
PCN115	Novartis Pharmaceuticals, East Hanover, NJ, USA	PCN195	None
PCN116	GlaxoSmithKline Biological S.A., Rixensart, Belgium; GlaxoSmithKline Slovakia, Bratislava, Slovak Republic	PCN196	The Netherlands Organisation for Health Research and Development, The Hague, The Netherlands; Roche The Netherlands, Woerden, The Netherlands; Pfizer The Netherlands, Capelle a/d IJssel, The Netherlands
PCN117	Novartis, Camberley, UK		Genentech, South San Francisco, CA, USA
PCN118	None	PCN197	Takeda, Roskilde, Denmark
PCN119	BMBF, Bonn, Germany	PCN198	GlaxoSmithKline, Cambridge, UK
PCN120	Janssen, Panama, Panama	PCN199	LifeCell Corporation, Bridgewater, NJ, USA
PCN121	Janssen, panama, Panama	PCN200	Ipsen Pharma GmbH, Ettlingen, Germany
PCN122	Novartis, Moscow, Russia	PCN201	Janssen Pharmaceuticals, Neuss, Germany
PCN123	Covance Inc., London, UK	PCN202	Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany
PCN124	None	PCN203	Health Research Board, Dublin, Ireland
PCN125	None	PCN204	Roche, Basel, Switzerland
PCN126	None	PCN205	Medivation, Inc., San Francisco, CA, USA; Astellas Pharma Global Development, Inc., Northbrook, IL, USA
PCN127	None	PCN206	None
PCN128	None	PCN207	None
PCN129	Helmholtz Zentrum München, Neuherberg, Germany	PCN208	None
PCN130	Sanofi Pasteur MSD, Lyon, France	PCN209	None
PCN131	None	PCN210	University of the Basque Country, UPV / EHU, Basque Country, Spain
PCN132	Takeda Pharmaceuticals, Zurich, Switzerland; T.I. Salud, Mexico City, Mexico		None
PCN133	None	PCN211	None
PCN134	None	PCN212	None
PCN135	None	PCN213	NIHR, Leeds, UK
PCN136	Pfizer China, Shanghai, China	PCN214	None
PCN137	University of Jordan, Amman, Jordan	PCN215	None
PCN138	Merck Serono, Feltham, UK; Merck Serono, Darmstadt, UK	PCN216	None
PCN140	None	PCN217	None
PCN141	None	PCN218	Main Association of Austrian Health Security Institutions, Vienna, Austria
PCN142	Psicofarma, Mexico City, Mexico	PCN219	Eli Lilly Italy, Florence, Italy
PCN143	Oncotrol, Innsbruck, Austria	PCN220	None
PCN144	Oncotrol, Innsbruck, Austria	PCN221	Roche F.Hoffmann-La Roche Ltd., Moscow, Russia
PCN145	Takeda Pharma, Solna, Sweden	PCN222	Novartis Hellas, Metamorfofi, Attica, Athens, Greece
PCN146	Laboratórios Pfizer Lda., Porto Salvo, Portugal	PCN223	None
PCN147	None	PCN224	None
PCN148	Carl-Zeiss, Oberkochen, Germany	PCN225	Decision Resources Group, Burlington, MA, USA
PCN149	None	PCN226	None
PCN150	Novartis, UK	PCN227	Eli Lilly and Company, Indianapolis, IN, USA
PCN151	Roche Hellas, Athens, Greece	PCN228	None
PCN152	Roche Pharmaceuticals, São Paulo, Brazil	PCN229	None
PCN153	None	PCN230	None
PCN154	Grindex, Moscow, Russia	PCN231	None
PCN155	Mundipharma GesmbH. Austria - organization unit Czech Republic, Prague, Czech Republic	PCN232	AstraZeneca, Zoetermeer, The Netherlands
PCN156	Boehringer Ingelheim, Alkmaar, The Netherlands	PCN233	MUSC Medication Safety Program, Charleston, SC, USA
PCN157	National Institute of Health Research, London, UK	PCN234	Genentech, Inc., South San Francisco, CA, USA
PCN158	Celgene International Sarl, Boudry, Switzerland	PCN235	None
PCN159	None	PCN236	GE Healthcare, Riyadh, Saudi Arabia
PCN160	None	PCN237	None
PCN161	Celgene, Summit, NJ, USA	PCN238	Amgen CEE Headquarters, Vienna, Austria
PCN162	None	PCN239	None
PCN163	Bristol-Myers Squibb, Rueil Malmaison, France	PCN240	GlaxoSmithKline Biologicals S.A., Rixensart, Belgium
PCN164	None	PCN241	None
PCN165	None	PCN242	None
PCN166	AdRes, Turin, Italy	PCN243	Boehringer Ingelheim, Bracknell, UK
PCN167	German Federal Ministry of Education and Research, Berlin, Germany	PCN244	None
PCN168	AstraZeneca UK Ltd., Luton, UK	PCN245	Amgen CEE Headquarters, Vienna, Austria
PCN169	Amgen Inc., Thousand Oaks, CA, USA	PCN246	None
PCN170	CTMM, Eindhoven, The Netherlands	PCN247	Alliance Life Sciences Consulting Group, Somerset, NJ, USA
PCN171	None	PCN248	Roche Pharma AG, Grenzach-Wyhlen, Germany
PCN172	None	PCN249	None
PCN173	Personalized Medicine Partnership for Cancer (PMPC), Montreal, QC, Canada	PCN250	None
PCN174	Amgen Inc., Thousand Oaks, CA, USA	PCN251	None
PCN175	None	PCN252	Roche, Welwyn Garden City, UK
PCN176	None	PCN253	IMS Consulting Group, Munich, Germany
PCN177	UBC, Dorval, Canada	PCN254	None
PCN178	AstraZeneca, Alderley Park, UK	PCN255	None
PCN179	Oxford PharmaGenesis Ltd., Tubney, Oxford, UK	PCN256	None
PCN180	Eisai Inc., Woodcliff Lake, NJ, USA	PCN257	None
PCN181	GILEAD, London, UK	PCN258	None
PCN182	AstraZeneca, Macclesfield, UK	PCN259	None
PCN183	DIUE de la Generalitat de Catalunya (2009 SGR 1095), Barcelona, Spain; Catalan Agency for Health Information, Assessment and Quality (grant AATRM 436/05/2008), Barcelona, Spain	PCN260	Costello Medical Consulting, Cambridge, UK
PCN184	Roche, Boulogne Billancourt, France	PCN261	None
PCN185	National Institute of public health and the environment, Bilthoven, The Netherlands	PCN262	Pharmaceutical Research and Manufacturers of America, Washington, DC, USA
PCN186	Institut de Recherche Pierre Fabre, Boulogne-Billancourt, France	PCN263	São Paulo Research Foundation (FAPESP), Sao Paulo, Brazil
PCN187	None	PCN264	None
		PCN265	None
		PCN266	Quintiles Consulting, Reading, UK
		PCN267	None

REFERENCE CODE	FINANCIAL SUPPORT	REFERENCE CODE	FINANCIAL SUPPORT
PCN268	Evidera, London, UK	PCV68	Medtronic spa, Sesto San Giovanni (MI), Italy
PCN269	European Commission, Brussels, The Netherlands	PCV69	Novartis, Dublin, Ireland
PCN270	Ministry of Health and Welfare, Sejong, South Korea	PCV70	CSL Behring, King of Prussia, PA, USA
PCN271	Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany	PCV71	None
PCN272	None	PCV72	CTMM, Eindhoven, The Netherlands; Dutch Heart Foundation, The Hague, The Netherlands; Dutch Organisation for Health Research and Healthcare Innovation, The Hague, The Netherlands
PCN273	Genomic Health, Inc., Redwood City, CA, USA	PCV74	None
PCN275	The Netherlands Organisation for Health Research and Development, the Hague, The Netherlands	PCV75	Institute of Cardiology, Warsaw, Poland
PCN276	None	PCV76	Medtronic Italia S.p.A., Sesto San Giovanni, Italy
PCN277	Oncotrol, Innsbruck, Austria; Austrian Federal Ministries of BMVIT/BMWFFJ, Vienna, Austria; Tiroler Zukunftsstiftung/Standortagentur Tirol, Innsbrucker, Austria	PCV77	None
PCN278	None	PCV78	Baxter, Utrecht, The Netherlands
PCN279	ZonMw, Den Haag, The Netherlands	PCV79	Boehringer-Ingelheim, Bogota, Colombia
PCN280	AstraZeneca, London, UK	PCV80	Vifor Pharma, Athens, Greece
PCN281	None	PCV81	None
PCV1	Daiichi Sankyo Europe GmbH, Munich, Germany	PCV82	Servier, Madrid, Spain
PCV2	Daiichi Sankyo Europe GmbH, Munich, Germany	PCV83	Bristol-Myers Squibb Italy, Rome, Italy; Pfizer Italia, Rome, Italy
PCV3	None	PCV84	University Sains Malaysia, Penang, Malaysia
PCV4	U.S. Food and Drug Administration, Silver Spring, MD, USA	PCV85	None
PCV5	None	PCV86	AstraZeneca, Hong Kong, Hong Kong
PCV6	Bayer Pharma AG, Berlin, Germany	PCV87	National Institutes of Health, Rockville, MD, USA
PCV7	None	PCV88	Bristol-Myers Squibb Italy, Rome, Italy; Pfizer Italia, Rome, Italy
PCV8	None	PCV89	CTMM, Eindhoven, The Netherlands; Dutch Heart Foundation, The Hague, The Netherlands
PCV9	Amgen, Thousand Oaks, CA, USA	PCV90	BMS, Princeton, NJ, USA; Pfizer, New York, NY, USA
PCV10	Medtronic Inc., Santa Rosa, CA, USA	PCV91	Grant of Ministry of Health, IGA NT11532 "Hodnoceni zdravotnických prostředků", Prague, Czech Republic
PCV11	Medtronic, Minneapolis, MN, USA	PCV92	None
PCV12	None	PCV93	Ferrer, Barcelona, Spain
PCV14	BMS, Princeton, NJ, USA; Pfizer, New York, NY, USA	PCV94	National Clinical Guideline Centre, London, UK
PCV15	National Evidence-based Healthcare Collaborating Agency, Seoul, South Korea	PCV95	Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany
PCV16	Proteus Digital Health, Redwood City, CA, USA	PCV96	Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany
PCV17	AstraZeneca, Mölndal, Sweden	PCV97	Bristol-Myers Squibb, Pfizer, Moscow, Russia
PCV18	Boehringer Ingelheim, Paris, France	PCV98	Boehringer Ingelheim, Ingelheim, Germany
PCV19	Pfizer Ltd., Surrey, UK	PCV99	Medical Research & Innovation LP, Thessaloniki, Greece;
PCV20	None	PCV100	Novartis Hellas, Athens, Greece
PCV21	Bayer Hispania, Barcelona, Spain		National Institute for Health Research (NIHR), HTA Programme, London, UK
PCV22	Pierre Fabre Médicament, Boulogne, France	PCV101	Medtronic Trading NL BV, Heerlen, The Netherlands
PCV23	Merck Shape & Dohme, Hoddesdon, UK	PCV102	None
PCV24	None	PCV103	Cardiome, Vancouver, Canada
PCV25	Bristol-Myers Squibb, Princeton, NJ, USA	PCV104	W.L.Gore & Associati S.r.l., Barcelona, Spain
PCV26	BMS, Rueil Malmaison, France	PCV105	Gedeon Richter, Budapest, Hungary
PCV27	National Heart, Lung, and Blood Institute, Bethesda, MD, USA; American Heart Association, Dallas, TX, USA	PCV106	Servier Poland Sp. z o.o., Warsaw, Poland
PCV28	Menarini, Florence, Italy	PCV107	LipoScience, Raleigh, NC, USA
PCV29	None	PCV108	Astrazeneca, Madrid, Spain
PCV30	Eli Lilly and Company, Indianapolis, IN, USA	PCV109	National Evidence-based Healthcare Collaborating Agency, Seoul, South Korea
PCV31	RAGS, Selangor, Malaysia	PCV110	Amgen, Inc., Thousand Oaks, CA, USA
PCV34	None	PCV111	Amgen, Inc., Thousand Oaks, CA, USA
PCV35	Amgen Inc., Thousand Oaks, CA, USA	PCV112	Sanofi-Aventis Deutschland GmbH, Berlin, Germany
PCV36	Pfizer, S.L.U., Madrid, Spain	PCV113	None
PCV37	Servier Poland Sp. z o.o., Warsaw, Poland	PCV114	Nuffic agency, The Hague, The Netherlands
PCV38	Proteus Digital Health, Redwood City, CA, USA	PCV115	National Health Insurance Service, Seoul, South Korea
PCV39	Bristol-Myers Squibb Italy, Rome, Italy; Pfizer Italia, Rome, Italy	PCV116	Novartis Pharma AG, Basel, Switzerland
PCV40	None	PCV117	Poznan University of Medical Sciences, Poznan, Poland
PCV41	Abbott Hellas, Athens, Greece	PCV118	Novartis Pharma AG, Basel, Switzerland
PCV42	Ipsen Pharma, Ettlingen, Germany	PCV119	Amgen Inc., Thousand Oaks, CA, USA
PCV43	None	PCV120	Daiichi Sankyo Europe GmbH, Munich, Germany
PCV44	None	PCV121	Daiichi Sankyo Europe GmbH, Munich, Germany
PCV45	The Medicines Company, Parsippany, NJ, USA	PCV122	None
PCV46	None	PCV123	None
PCV47	None	PCV124	None
PCV48	Abbott Vascular, Rungis, France	PCV125	None
PCV49	diaDexus, San Francisco, CA, USA	PCV126	None
PCV50	Heart and Stroke Foundation of Canada, Toronto, ON, Canada	PCV127	CVS, Woonsocket, RI, USA
PCV51	None	PCV128	Belgian Stroke Council, Hasselt, Belgium
PCV52	None	PCV129	None
PCV53	Sorin Group Italia, Milano, Italy	PCV130	Servier, Paris, France
PCV54	National Health and Medical Research Council, Canberra, Australia	PCV131	Bayer Vital GmbH, Leverkusen, Germany
PCV55	None	PCV132	Department of Health, Vitoria-Gasteiz, Spain; FIS, Madrid, Spain
PCV56	Medtronic, Inc., Mounds View, MN, USA	PCV133	Bristol-Myers Squibb, Princeton, NJ, USA
PCV57	Medtronic, Sesto S.Giovanni, Italy; Medtronic, Meerbusch, Germany; Medtronic, Madrid, Spain; Medtronic, Warsaw, Poland; Medtronic, Maastricht, The Netherlands	PCV134	None
PCV58	Ministry of Health of the Czech Republic, Prague, Czech Republic	PCV135	Daiichi Sankyo Europe, Munich, Germany
PCV59	Boehringer-Ingelheim France, Paris, France	PCV136	Pfizer, Istanbul, Turkey
PCV60	Bristol-Myers Squibb, Rueil-Malmaison, France; Pfizer, Paris, France	PCV137	None
PCV61	CSL Behring, King of Prussia, PA, USA	PCV138	Poznan University of Medical Sciences, Poznan, Poland
PCV62	Medtronic Iberia, Madrid, Spain	PCV139	Daiichi Sankyo Europe GmbH, Munich, Germany
PCV63	None	PCV140	Daiichi Sankyo Europe GmbH, Munich, Germany
PCV64	Novartis Pharma AG, Basel, Switzerland	PCV141	None
PCV65	None	PCV142	Amgen, Inc., Thousand Oaks, CA, USA
PCV66	Gedeon Richter, Budapest, Hungary	PCV143	Bayer Healthcare Co. Ltd., Beijing, China
PCV67	BMBF, Bonn, Germany	PCV144	Bayer Healthcare Co. Ltd., Beijing, China
		PCV145	The Netherlands Organization for Health Research and Development, The Hague, The Netherlands
		PCV146	None

REFERENCE CODE	FINANCIAL SUPPORT	REFERENCE CODE	FINANCIAL SUPPORT
PCV147	None	PDB46	Novartis, Barcelona, Spain
PCV148	None	PDB47	Food and Health Bureau, Hong Kong, China
PCV149	None	PDB48	None
PCV150	Pfizer Health Research Foundation, Tokyo, Japan	PDB49	Novo Nordisk (China) Pharmaceuticals Co., Ltd., Beijing, China
PCV151	Institute for Health Economics and Policy, Tokyo, Japan	PDB50	None
PCV152	German Federal Ministry of Education and Research (BMBF), Berlin, Germany	PDB51	Sanofi, Madrid, Spain
PCV153	Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany	PDB52	None
PCV154	None	PDB53	None
PCV155	HSE Medicines Management Programme, Dublin, Ireland	PDB54	None
PCV156	None	PDB55	None
PCV157	None	PDB56	Independant Health Insurance Fund, Brussels, Belgium
PCV158	Mckinsey & Co, London, UK	PDB57	None
PCV159	None	PDB58	None
PCV160	None	PDB59	BC Pharma B.V., Moscow, Russia
PCV161	Bristol-Myers Squibb, Princeton, NJ, USA; Pfizer, New York, NY, USA	PDB60	Becton, Dickinson and Company, Shanghai, China
PCV162	Amgen, Inc., Thousand Oaks, CA, USA	PDB61	None
PCV163	FCT PTDC/SAU-ESA/103511/2008, Lisbon, Portugal; Pest-OE/MAT/UI0006/2011, Lisbon, Portugal	PDB62	Janssen A/S, Birkerød, Denmark
PCV164	The European Health Technology Institute for Socio-Economic Research, Brussels, Belgium	PDB63	Novo Nordisk, Madrid, Spain
PCV165	None	PDB64	Novo Nordisk, Madrid, Spain
PCV166	Novartis, Athens, Greece	PDB65	None
PCV167	University of Geneva Hospitals, Geneva, Switzerland	PDB66	AstraZeneca UK, Luton, UK
PCV168	Heart and Stroke Foundation of Canada, Toronto, ON, Canada; Alberta Provincial Stroke Strategy, Edmonton, AB, Canada	PDB67	AstraZeneca UK, Luton, UK
PCV170	Heart and Stroke Foundation of Canada, Toronto, ON, Canada; Alberta Provincial Stroke Strategy, Edmonton, ON, Canada	PDB68	Janssen A/S, Birkerød, Denmark
PCV171	UBC: An Express Scripts Company, Montreal, Canada	PDB69	Janssen, Paris, France
PCV172	Medtronic Iberia, Madrid, Spain	PDB70	AstraZeneca plc, Molndal, Sweden
PCV173	Abbott Nutrition, Columbus, OH, USA	PDB71	Janssen, High Wycombe, UK
PCV174	Orbus Neich, Hong Kong, China	PDB72	Medtronic, Tolochenaz, Switzerland
PCV175	Boehringer Ingelheim France, Paris, France	PDB73	AstraZeneca UK, Luton, UK
PCV176	None	PDB74	Novo Nordisk, Athens, Greece
PCV177	None	PDB75	Janssen A/S, Birkerød, Denmark
PCV178	Merck Sharp & Dohme, Oeiras, Portugal	PDB76	Janssen-Cilag Ltd., Dublin, Ireland
PCV179	Novartis Pharma AG, Basel, Switzerland	PDB77	Janssen-Cilag Ltd., Dublin, Ireland
PCV180	None	PDB78	Janssen A/S, Birkerød, Denmark
PCV181	Daiichi Sankyo Europe GmbH, Munich, Germany	PDB79	Medtronic, Tolochenaz, Switzerland
PCV182	Bristol-Myers Squibb, New York, NY, USA	PDB80	National Board of Health, Copenhagen, Denmark
PCV183	Amgen, Zug, Switzerland	PDB81	Janssen-Cilag Ltd., Dublin, Ireland
PDB1	Merck Sharpe & Dohme, Oeiras, Portugal	PDB82	Janssen, Warsaw, Poland
PDB2	Merck Sharp & Dohme, Oeiras, Portugal	PDB84	BC Pharma B.V., Moscow, Russia
PDB3	Novo Nordisk Farma, Espoo, Finland	PDB85	Janssen A/S, Birkerød, Denmark
PDB4	Merck Sharp & Dohme, Oeiras, Portugal	PDB86	National Institute for Health Research, London, UK
PDB5	Boehringer-Ingelheim, Ingelheim am Rhein, Germany	PDB87	AstraZeneca UK Ltd., Luton, UK
PDB6	Boehringer-Ingelheim, Ingelheim am Rhein, Germany	PDB88	AstraZeneca UK Ltd., Luton, UK
PDB7	Boehringer-Ingelheim, Ingelheim am Rhein, Germany	PDB89	AstraZeneca UK Ltd., Luton, UK
PDB8	Bayer HealthCare AG, Moscow, Russia	PDB90	None
PDB9	None	PDB91	Novartis Farmaceutica, Barcelona, Spain
PDB11	None	PDB92	Medtronic International Trading Sarl, Tolochenaz, Switzerland
PDB12	Bristol-Myers Squibb, New York, NY, USA	PDB93	Medtronic International Trading Sarl, Tolochenaz, Switzerland
PDB13	Gt. Jj, Albania	PDB94	None
PDB14	None	PDB95	AstraZeneca UK Ltd., Luton, UK
PDB15	None	PDB96	Ipsen, Athens, Greece
PDB17	Janssen Research & Development, Beerse, Belgium	PDB97	MSD, Italy
PDB18	MSD, Courbevoie, France	PDB98	AstraZeneca UK Ltd., Luton, UK
PDB19	Eli Lilly and Company, Windlesham, UK	PDB99	Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA
PDB20	Qatar National Research Fund, Doha, Qatar	PDB100	Astra Zeneca, Levent-Istanbul, Turkey
PDB21	None	PDB101	AstraZeneca, Madrid, Spain
PDB22	Sanofi, Paris, France	PDB102	None
PDB23	Novartis Farmaceutica, Barcelona, Spain	PDB103	NIHR, London, UK
PDB24	None	PDB104	AstraZeneca, Madrid, Spain
PDB25	Becton, Dickinson and Company, Shanghai, China	PDB105	AstraZeneca, Madrid, Spain
PDB26	Novartis, Barcelona, Spain	PDB106	Otsuka Pharmaceutical Europe Ltd., Wexham, UK
PDB27	Pharma Industry Finland, Helsinki, Finland	PDB107	Boehringer Ingelheim, Ingelheim am Rhein, Germany
PDB28	Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany	PDB108	Abbott Diabetes Care, Alameda, CA, USA
PDB29	None	PDB109	Janssen, Warszawa, Poland
PDB30	Novo Nordisk B.V., Alphen a/d Rijn, The Netherlands	PDB110	Boehringer Ingelheim, Ingelheim am Rhein, Germany
PDB31	Merck Sharp & Dohme, Oeiras, Portugal	PDB111	National Science Centre, Cracow, Poland
PDB32	None	PDB112	Eli Lilly, Toronto, ON, Canada; Becton Dickinson, Mississauga, ON, Canada; Novo Nordisk, Mississauga, ON, Canada; Sanofi, Laval, QC, Canada
PDB33	Astra Zeneca, Sofia, Bulgaria	PDB113	Allergan, Roma, Italy
PDB34	Takeda Pharmaceuticals, Zurich, Switzerland	PDB114	None
PDB35	Bayer HealthCare AG, Moscow, Russia	PDB115	Merck Sharp & Dohme, Oeiras, Portugal
PDB36	Ethicon Global Surgery, Cincinnati, OH, USA	PDB116	Biodel Inc., Danbury, CT, USA
PDB37	AstraZeneca, Södertälje, Sweden	PDB117	Merck Sharp & Dohme, Oeiras, Portugal
PDB38	Pfizer, S.L.U., Madrid, Spain	PDB118	Merck Sharp & Dohme, Whitehouse Station, NJ, USA
PDB39	EMD Serono, Inc., Rockland, MA, USA	PDB119	Medtronic, Milano, Italy
PDB40	ResMed Germany Inc., Martinsried, Germany	PDB120	Merck Sharp & Dohme, Whitehouse Station, NJ, USA
PDB41	None	PDB121	Merck Sharp & Dohme, Whitehouse Station, NJ, USA
PDB42	None	PDB122	None
PDB43	Abbot Diabetes Care, Madrid, Spain	PDB123	None
PDB44	Abbott Diabetes Care, Madrid, Spain	PDB124	Otsuka Pharmaceutical Europe Ltd., Wexham, UK
PDB45	Merck Sharp & Dohme, Oeiras, Portugal	PDB125	Eli Lilly and Company, Indianapolis, IN, USA
		PDB126	None
		PDB127	None
		PDB128	Boehringer Ingelheim, Ingelheim, Germany
		PDB129	Novo Nordisk Limited, Copenhagen, Denmark
		PDB130	AstraZeneca, Hamburg, Germany
		PDB131	AstraZeneca, Hamburg, Germany

REFERENCE CODE	FINANCIAL SUPPORT	REFERENCE CODE	FINANCIAL SUPPORT
PDB132	Ipsen, Boulogne Billancourt, France	PGI44	AbbVie, Campoverde di Aprilia (LT), Italy
PDB133	Novartis Farmaceutica, Barcelona, Spain	PGI45	Laboratorios Almirall, S.A., Barcelona, Spain
PDB134	None	PGI46	Bristol-Myers KK, Tokyo, Japan
PDB135	None	PGI47	None
PDB136	Novartis, Basel, Switzerland	PGI48	Gilead BVBA, Diegem, Belgium
PDB137	Novartis Hellas SA, Metamorfosis, Greece	PGI49	Sucampo, Zug, Switzerland
PDB138	Novo Nordisk IO, Zurich, Switzerland	PGI50	Gilead, Lisbon, Portugal
PDB139	Janssen-Cilag A/S, Birkerød, Denmark	PGI52	Ironwood Pharmaceuticals, Cambridge, MA, USA
PDB140	None	PGI53	Ministry of Health and Welfare, Sejong, South Korea
PDB141	Novartis Hellas SA, Metamorfosis, Greece	PGI54	Ministry of Health, Labour and Welfare, Tokyo, Japan
PDB142	None	PGI55	None
PDB143	None	PGI56	Gilead Sciences, Foster City, CA, USA
PDB144	Novo Nordisk Hellas Ltd., Athens, Greece	PHP1	None
PDB145	Novo Nordisk Hellas Ltd., Athens, Greece	PHP2	None
PDB146	None	PHP3	None
PDB147	Truven Health Analytics, Bethesda, MD, USA	PHP4	None
PDB148	Novartis Hungary, Budapest, Hungary	PHP5	SR0P-4.2.2.C-11/1/KONV-2012-0005, Well-being in the
PDB149	None		Information Society, Budapest, Hungary
PDB150	None	PHP6	Quintiles Commercial Germany GmbH, Mannheim, Germany;
PDB151	Medtronic Inc., Istanbul, Turkey		Healthcare Manufaktur GmbH, Cologne, Germany
PDB152	None	PHP8	None
PDB154	None	PHP9	None
PDB155	Charles University in Prague, Hradec Kralove, Czech Republic	PHP10	Novartis Farma Italy, Saronno VA, Italy
PDB156	GlaxoSmithKline, London, UK	PHP11	None
PDB157	AstraZeneca, Mölndal, Sweden	PHP12	None
PDB158	None	PHP13	None
PDB159	Biodel Inc., Danbury, CT, USA	PHP14	None
PDB160	MSD Ltd., Hoddesdon, UK	PHP15	None
PDB161	Takeda UK Ltd., London, UK	PHP16	None
PDB162	None	PHP17	None
PDB163	None	PHP18	None
PDB164	None	PHP19	None
PDB165	None	PHP20	None
PDB166	None	PHP21	National Institute for Health Research, London, UK
PDB167	None	PHP22	None
PDB169	IHS, Englewood, CO, USA	PHP23	None
PDB170	Ministry of Health and Welfare, Sejong-si, South Korea	PHP24	None
PDB171	None	PHP25	Novartis, Dubai, United Arab Emirates
PDB172	Merck Sharp & Dohme Ltd., Hoddesdon, UK	PHP26	Pan Hellenic Union of Pharmaceutical Industry, Athens, Greece
PDB173	Bristol-Myers Squibb, New York, NY, USA	PHP27	None
PDB174	Roche Diagnostics GmbH, Mannheim, Germany	PHP28	European Generics Association, Brussels, Belgium
PGI1	None	PHP29	None
PGI2	None	PHP30	None
PGI3	Merck, Whitehouse Station, NJ, USA	PHP31	None
PGI4	Pfizer Japan Inc., Tokyo, Japan	PHP32	None
PGI5	Leona M. and Harry B. Helmsley Charitable Trust, New York, NY, USA	PHP33	None
	Merck, Whitehouse Station, NJ, USA	PHP34	None
PGI6	None	PHP35	None
PGI7	Egis Pharmaceuticals PLC, Budapest, Hungary	PHP37	None
PGI8	NRF, Pretoria, South Africa	PHP38	None
PGI9	Janssen, Sao Paulo, Brazil	PHP39	None
PGI10	Bristol-Myers Squibb, Rueil-Malmaison, France	PHP40	Medtronic Inc., Istanbul, Turkey
PGI11	Bristol-Myers Squibb, Rueil-Malmaison, France	PHP41	Pan Hellenic Union of Pharmaceutical Industry, Athens, Greece
PGI12	AstraZeneca, London, UK	PHP42	Qatar National Research Fund, Doha, Qatar
PGI13	Laboratorios Almirall, S.A., Barcelona, Spain	PHP43	None
PGI14	None	PHP44	None
PGI15	Almirall, London, UK	PHP45	None
PGI16	Barking, Havering and Redbridge University Hospitals NHS Trust, Queen's Hospital, Romford, UK	PHP47	None
PGI17	Almirall S.A., Barcelona, Spain	PHP49	None
	MSD Pharmaceuticals, Moscow, Russia	PHP51	None
PGI18	Sucampo, Zug, Switzerland	PHP54	None
PGI19	Almirall, Lisbon, Portugal	PHP55	None
PGI20	Roche, Monza, Italy	PHP56	None
PGI21	Gilead, Lisbon, Portugal	PHP57	None
PGI22	Johnson&Johnson LLC, Moscow, Russia	PHP58	Boehringer-Ingelheim, Barcelona, Spain
PGI23	None	PHP59	None
PGI24	Gilead, Istanbul, Turkey	PHP60	German Pharmaceutical Industry Association, Berlin, Germany
PGI25	Novartis, Basel, Switzerland	PHP61	None
PGI26	None	PHP62	None
PGI27	None	PHP63	German Federal Ministry of Education and Research (BMBF), Berlin, Germany
PGI28	None		
PGI29	Gilead Sciences, Tokyo, Japan	PHP64	None
PGI30	None	PHP65	None
PGI31	None	PHP66	None
PGI32	None	PHP67	None
PGI33	Gilead Pharmaceutical, London, UK	PHP68	None
PGI34	AbbVie, North Chicago, IL, USA	PHP69	None
PGI35	The Royal Golden Jubilee Ph.D. Program, Bangkok, Thailand	PHP70	None
PGI36	AstraZeneca, London, UK	PHP71	Verband Forschender Arzneimittelhersteller e.V., Berlin, Germany
PGI37	Sucampo, Zug, Switzerland	PHP72	None
PGI38	Lumbardy region, Milan, ID, Italy	PHP73	None
PGI39	None	PHP74	None
PGI40	Merck, Whitehouse Station, NJ, USA	PHP75	Universidad Nacional de Colombia, Bogotá, Colombia
PGI41	None	PHP76	None
PGI42	Forest Research Institute, Jersey City, NJ, USA; Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA	PHP77	None
	None	PHP78	None
PGI43	None	PHP79	None

REFERENCE CODE	FINANCIAL SUPPORT	REFERENCE CODE	FINANCIAL SUPPORT
PHP80	AXIS Healthcare Consulting Ltd., Galway, Ireland	PHP169	Great Lakes University of Kisumu, Kisumu, Kenya; KEMRI/CDC, Nairobi, Kenya
PHP81	None	PHP170	None
PHP82	None	PHP171	None
PHP83	None	PHP172	Great Lakes University of Kisumu, Kisumu, Kenya
PHP84	None	PHP173	None
PHP86	Roche Products Limited, Welwyn Garden City, UK	PHP174	Hellenic Association of Pharmaceutical Companies, Athens, Greece
PHP87	LifeCell Corporation, Bridgewater, NJ, USA	PHP175	None
PHP88	Boehringer Ingelheim, Bracknell, UK	PHP176	None
PHP89	Eisai, Inc., Woodcliff Lake, NJ, USA	PHP177	Evidera, London, UK
PHP90	None	PHP178	None
PHP91	Janssen Cilag, Neuss, Germany	PHP179	St. Luke's Life Science Institute, Tokyo, Japan
PHP92	None	PHP180	Great Lakes University of Kisumu, Kisumu, Kenya; KEMRI/CDC, Kisumu, Kenya
PHP93	None	PHP181	Great Lakes University of Kisumu, Kisumu, Kenya
PHP94	None	PHP182	None
PHP95	None	PHP183	Novartis Pharma AG, Basel, Switzerland
PHP96	None	PHP184	None
PHP97	None	PHP185	European Commission, Bruxelles, Belgium
PHP98	None	PHP186	None
PHP100	None	PHP187	None
PHP101	PAREXEL International, Uxbridge, UK	PHP190	None
PHP102	None	PHP191	None
PHP103	None	PHP192	None
PHP104	None	PHP193	None
PHP105	None	PHP194	None
PHP106	None	PHP195	IHS, London, UK
PHP107	IHS, London, UK	PHP196	None
PHP108	None	PHP197	Janssen-Cilag GmbH, Neuss, Germany
PHP109	Association of the British Pharmaceutical Industry, London, UK	PHP198	None
PHP110	None	PHP199	None
PHP111	None	PHP200	National Institute for Health Research, London, UK
PHP112	None	PHP201	Universiti Sains Malaysia, Penang, Malaysia
PHP114	Regional Government (Galicia, Spain), Santiago de Compostela, Spain	PHP202	None
PHP115	None	PHP203	None
PHP116	None	PHP204	None
PHP117	None	PHP205	None
PHP118	Chang Gung Memorial Hospital, Tao-Yuan, Taiwan	PHP206	Pharmaceutical Research and Manufacturers of America, Washington DC, USA
PHP119	CareFusion France, Voisins-le-Brétoneux, France	PHP207	Pfizer s.r.o., Prague, Czech Republic
PHP120	None	PHP208	None
PHP121	None	PHP209	None
PHP122	Pfizer Pharma GmbH, Berlin, Germany	PHP210	Roche Pharma AG, Grenzach Wyhlen, Germany
PHP123	None	PHP211	None
PHP124	None	PHP212	None
PHP125	None	PHP214	None
PHP126	None	PHP215	None
PHP127	None	PHP216	None
PHP128	French National Authority of Health (HAS), Paris, France	PHP217	European Health Technology Institute, Brussels, Belgium
PHP129	None	PHP218	None
PHP130	None	PHP219	None
PHP131	None	PHP220	Pfizer, Tadworth, UK
PHP132	None	PHP221	Roche Products Pty Ltd., Dee Why NSW, Australia
PHP133	SRH Research Foundation, Heidelberg, Germany	PHP223	None
PHP134	None	PHP224	Haute Autorité de Santé, Saint-Denis, France
PHP135	None	PHP225	Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
PHP136	None	PHP226	None
PHP137	None	PHP227	None
PHP139	Roche Pharma AG, Grenzach-Wyhlen, Germany	PHP228	None
PHP140	None	PHP229	IHS, London, UK
PHP141	None	PHP230	None
PHP142	None	PHP231	None
PHP143	None	PHP232	None
PHP144	None	PHP233	IHS, London, UK
PHP145	Creativ-Ceutical Ltd., London, UK	PHP234	None
PHP146	None	PHP235	None
PHP147	None	PHP236	None
PHP148	Johnson & Johnson Healthcare Systems Inc., Horsham, PA, USA	PHP237	FIOTEC, Brasilia, Brazil
PHP149	Astellas Pharma Europe Ltd., Chertsey, UK	PHP238	Janssen-Cilag GmbH, Neuss, Germany
PHP150	Novartis Pharma AG, Basel, Switzerland	PHP240	Market Access Solutions, London, UK
PHP151	None	PHP241	None
PHP152	Market Access Solutions LLC, Raritan, NJ, USA	PHP242	Sorbonne Paris Cité University Network, Paris, France; EHESP French School of Public Health, Rennes, France
PHP153	None	PHP243	None
PHP154	Medtronic, Istanbul, Turkey	PHP244	None
PHP155	None	PHP245	FIOTEC, Brasilia, Brazil
PHP156	None	PHP246	IMS HEALTH GmbH & Co. OHG, Munich, Germany
PHP157	None	PHP247	None
PHP158	None	PHP248	Top Institute Pharma, Leiden, The Netherlands
PHP159	None	PHP249	European Commission, Consumers, Health and Food Executive Agency, Luxembourg
PHP160	None	PHP250	None
PHP161	None	PHP251	None
PHP162	None	PHP252	None
PHP163	Novartis Pharma AG, Basel, Switzerland		
PHP164	None		
PHP165	None		
PHP166	None		
PHP167	None		
PHP168	IHS, London, UK		

REFERENCE CODE	FINANCIAL SUPPORT	REFERENCE CODE	FINANCIAL SUPPORT
PHP253	None	PIH44	None
PHP254	None	PIH45	None
PHP255	None	PIH46	None
PHP256	None	PIH47	Covance, San Diego, CA, USA
PHP257	None	PIH48	None
PHP258	AstraZeneca, Madrid, Spain	PIH49	None
PHP259	None	PIH50	None
PHP260	None	PIH51	Health Research Board, Dublin, Ireland
PHP261	None	PIH52	National Institute of Health Research, Southampton, UK
PHP263	German Federal Ministry of Economics and Technology, Berlin, Germany	PIH53	Solvay Pharma, Hannover, Germany
PHP264	None	PIH54	Creativ-Ceutical, London, UK
PHP265	None	PIH55	None
PHP266	None	PIH56	None
PHP267	Research-Based Pharmaceutical Companies (Rx&D), Toronto, ON, Canada	PIH57	None
PHP268	None	PIH58	None
PHP270	None	PIH59	None
PHP271	None	PIH60	None
PHP272	None	PIH61	None
PHP273	GlaxoSmithKline, Wavre, Belgium; Deloitte, Diegem, Belgium	PIH62	None
PHP274	Pfizer UK Ltd., Walton Oaks, UK	PIH63	Qatar University, Doha, Qatar
PHP275	Sanofi Pasteur MSD, Lyon, France	PIH64	None
PHP277	None	PIH65	None
PHP278	None	PIH66	None
PHP279	GlaxoSmithKline Biologicals S.A., Rixensart, Belgium	PIH67	None
PHP280	None	PIH68	None
PHP281	None	PIH69	KJT Group, Honeoye Falls, NY, USA
PHP282	Quintiles Consulting, Hawthorne, NY, USA	PIH70	None
PHP283	None	PIH71	EuroQol Foundation, Rotterdam, The Netherlands; Fondo Nacional de Recursos, Montevideo, Uruguay
PHP284	None	PIH72	None
PHP285	None	PIH73	None
PHP286	None	PIH74	Mapi, Lyon, France
PHP287	None	PIH75	Bayer Yakuhin, Ltd., Osaka, Japan
PHP288	None	PIH76	Exco InTouch, Nottingham, UK
PHP289	None	PIH77	Novartis Pharma AG, Basel, Switzerland
PHP290	None	PIH78	None
PHP291	None	PIH79	None
PHP295	None	PIH80	None
PHP296	None	PIH81	Nestle Health Science, Barcelona, Spain
PHP297	Medtronic, Istanbul, Turkey	PIH82	None
PIH1	None	PIH83	National Health and Medical Research Council, ACT, Australia
PIH2	None	PIH84	Eli Lilly and Company, Indianapolis, IN, USA
PIH3	Novartis Pharma, Nuremberg, Germany	PIH85	Anvisa, Brasília, Brazil
PIH4	Astellas, Leiden, The Netherlands	PIH86	ANVISA, Brasília, Brazil
PIH5	None	PIH87	Department of Health and Social Action (DSAS) of the canton of Vaud, Canton of Vaud, Switzerland
PIH6	National Institute for Health Research, London, UK	PIH88	None
PIH7	None	PIH89	EMD Serono, Inc., Rockland, MA, USA
PIH8	Agency for Integrated Care, Singapore, Singapore	PIH90	None
PIH10	None	PIH91	None
PIH11	None	PIH92	None
PIH13	None	PIH93	None
PIH14	FP7-HEALTH, EU, Ireland	PIH94	Pfizer, S.L.U., Madrid, Spain; Spanish Association for the Study of Menopause, Madrid, Spain; Universidad Autónoma de Madrid, Madrid, Spain
PIH15	State of Vermont Green Mountain Care Board, Montpelier, VT, USA	PIH95	Taipei City Department of Health, Taipei, Taiwan
PIH16	Nestle Health Science, Barcelona, Spain	PIH96	GlaxoSmithKline Vaccines, Wavre, Belgium
PIH17	None	PIH97	Covance Market Access Services, Gaithersburg, MD, USA
PIH18	None	PIH98	None
PIH19	None	PIH99	Eli Lilly and Company, Basingstoke, UK
PIH20	GlaxoSmithKline, Warsaw, Poland	PIN1	Janssen, Beerse, Belgium
PIH21	None	PIN2	Cubist Pharmaceuticals, Lexington, MA, USA
PIH22	Abbott, Moscow, Russia	PIN3	None
PIH23	Merck Sharp and Dohme, Hoddesdon, UK	PIN4	The Medicines Company, Parsippany, NJ, USA
PIH24	Ferring Pharmaceuticals Poland Sp. z o. o., Warsaw, Poland	PIN5	Sanofi Pasteur, Lyon, France
PIH25	SPMSD, Lyon, France	PIN6	None
PIH26	AMS, Madrid, Spain	PIN7	None
PIH27	None	PIN8	Astellas Pharma Kft., Budapest, Hungary
PIH28	Merck & Co., Inc., West Point, PA, USA	PIN9	Janssen EMEA, Beerse, Belgium
PIH29	GlaxoSmithKline S.R.L., Bucharest, Romania	PIN11	None
PIH30	None	PIN12	None
PIH31	None	PIN13	THRIVE, KAMPALA, Uganda
PIH32	Ministry of Health and Social Protection, Bogota, Colombia; Administrative Department of Science, Technology and Innovation, Colciencias, Bogota, Colombia	PIN14	Bristol Myers Squibb, New Jersey, NJ, USA
PIH33	Gedeon Richter Romania SA, Corunca, Romania	PIN15	GalxoSmithKline Biologicals SA, Rixensart, Belgium
PIH34	HRA Pharma, Paris, France	PIN16	None
PIH35	Besins, São Paulo, Brazil	PIN17	None
PIH36	None	PIN18	GlaxoSmithKline Biologicals S.A., Rixensart, Belgium
PIH37	None	PIN19	None
PIH38	Medical University Astana, Astana, Kazakhstan	PIN20	Cubist Pharmaceuticals, Lexington, MA, USA
PIH39	Federal Ministry of Education and Research, Berlin, Germany	PIN21	Johnson & Johnson Medical, Madrid, Spain
PIH40	None	PIN22	None
PIH41	Pierre Fabre Italia S.p.a., Milan, Italy	PIN23	Pfizer Brasil, São Paulo, Brazil
PIH42	Sanofi Pasteur, ROME, Italy	PIN24	None
PIH43	Consejo General de Colegios Oficiales de Farmaceuticos, Madrid, Spain; Laboratorios Cinfa, Navarra, Spain	PIN25	Astellas Pharma a/s, Kastrup, Denmark
		PIN26	Sanofi Pasteur MSD, Lyon, France
		PIN27	Pfizer, Inc., São Paulo, Brazil

REFERENCE CODE	FINANCIAL SUPPORT	REFERENCE CODE	FINANCIAL SUPPORT
PIN28	Sanofi, Sao Paulo, Brazil	PIN109	NHS R&D Health Technology Assessment (HTA) Programme, Southampton, UK
PIN29	None	PIN111	None
PIN30	None	PIN112	Decision Resources Group, Burlington, MA, USA
PIN31	Ministry of Health, Labour and Welfare, Tokyo, Japan	PIN113	GlaxoSmithKline Biologicals, Rixensart, Belgium
PIN32	None	PIN114	Merck and Co., Inc., West Point, PA, USA
PIN33	Pfizer Deutschland GmbH, Berlin, Germany	PIN115	Health Research Board, Dublin, Ireland
PIN34	Delta Medical Promotions, Moscow, Russia	PIN116	AstraZeneca UK Ltd., Luton, UK
PIN35	GlaxoSmithKline Biologicals S.A., Rixensart, Belgium	PIN117	Federal Ministry of Education and Research (BMBF), Berlin, Germany; Ministry of Education, Science and Culture of the state Mecklenburg-Western Pomerania, Schwerin, Germany
PIN36	Johnson and Johnson Sihhi Malzeme San. ve Tic. Ltd. Sti., Istanbul, Turkey	PIN118	None
PIN37	Johnson and Johnson Sihhi Malzeme San. ve Tic. Ltd. Sti., Istanbul, Turkey	PIN119	None
PIN38	Pfizer Inc., Beijing, China	PIN120	None
PIN39	Astellas Pharma a/s, Kastrup, Denmark	PIN121	None
PIN40	Robert Koch Institute, Berlin, Germany	PIN122	None
PIN41	None	PIN123	BMGF, Seattle, DC, USA
PIN42	Pfizer, New York, NY, USA	PIN124	None
PIN43	None	PIN125	None
PIN44	AstraZeneca GmbH, Wedel, Germany	PMH1	Lundbeck Italia S.p.A., Milano, Italy
PIN45	None	PMH2	Ministry of Health and Welfare, Seoul, South Korea
PIN46	None	PMH3	MyCognition, London, UK
PIN47	None	PMH4	Innovatiefonds Zorgverzekeraars, Zeist, The Netherlands
PIN48	Sanofi Pasteur MSD, Lyon, France	PMH5	Shire Development LLC, Wayne, PA, USA
PIN49	None	PMH6	Cheplapharm Arzneimittel GmbH, Greifswald - Insel Riems, Germany
PIN50	None	PMH7	Eli Lilly and Company Ltd., Indianapolis, IN, USA
PIN51	None	PMH8	NIHR, Southampton, UK; MRC ConDuCT Hub for Trials Methodology Research, Swindon, UK
PIN52	Roche Diagnostics S.p.A, Milan, Italy	PMH9	National Institute for Health Research, Southampton, UK
PIN53	GlaxoSmithKline S.A., Madrid, Spain; GlaxoSmithKline – Produtos Farmacêuticos, Lda., Lisbon, Portugal	PMH10	Eli Lilly and Company Ltd., Indianapolis, IN, USA
PIN54	GlaxoSmithKline d.o.o., družba za promet s farmacevtskimi izdelki, Ljubljana, Slovenia	PMH11	None
PIN55	Gilead Sciences The Netherlands, Amsterdam, The Netherlands	PMH12	Ministry of Health, Labour and Welfare, Japan, Tokyo, Japan
PIN56	GlaxoSmithKline Biologicals SA, Wavre, Belgium	PMH13	None
PIN57	Astellas Pharma a/s, Kastrup, Denmark	PMH14	Janssen-Cilag GmbH, Neuss, Germany
PIN58	Pfizer Inc., Collegeville, PA, USA	PMH15	Roche Farma, Madrid, Spain
PIN59	Sanofi Pasteur, Rome, Italy	PMH16	Janssen Global Services, New Jersey, NJ, USA
PIN60	Astellas Pharma, MADRID, Spain	PMH17	Reckitt Benckiser, Richmond, VA, USA
PIN61	AstraZeneca, Rueil-Malmaison, France	PMH18	Janssen, Sao Paulo, Brazil
PIN62	Janssen-Cilag, Neuss, Germany	PMH19	Janssen Inc., Toronto, ON, Canada
PIN63	None	PMH20	Janssen-Cilag AG, Zug, Switzerland
PIN64	Astellas Pharma, Budapest, Hungary	PMH21	Mundipharma International Limited, Cambridge, UK
PIN65	Merck Sharp & Dohme, Athens, Greece	PMH22	Janssen-Cilag GmbH, Neuss, Germany
PIN66	Gilead Sciences, Foster City, CA, USA	PMH23	Lilly Suzhou Pharmaceutical Company, Ltd., Shanghai, China
PIN67	Gilead Sciences, Foster City, CA, USA	PMH24	Eli Lilly, Windlesham, UK
PIN68	GlaxoSmithKline Biologicals S.A., Rixensart, Belgium	PMH25	Lundbeck, Issy-les-Moulineaux, France
PIN69	GlaxoSmithKline Biologicals SA, Rixensart, Belgium	PMH26	NIHR HTA programme, Southampton, UK
PIN70	Sanofi Pasteur MSD, Madrid, Spain	PMH27	Lundbeck Hellas SA, Athens, Greece
PIN71	None	PMH28	Eli Lilly and Company, Windlesham, UK
PIN72	GlaxoSmithKline d.o.o., družba za promet s farmacevtskimi izdelki, Ljubljana, Slovenia	PMH29	Janssen-Cilag GmbH, Neuss, Germany
PIN73	Gilead Sciences The Netherlands, Amsterdam, The Netherlands	PMH30	National Institute for Health Research HTA Programme, Southampton, UK; University of Sheffield, Sheffield, UK
PIN74	GlaxoSmithKline, Wavre, Belgium	PMH31	National Institute for Health Research, Southampton, UK
PIN75	BD, Shanghai, China	PMH32	The National Institute for Health Research - Health Technology Assessment HTA Programme, London, UK
PIN76	Merck Sharp & Dohme, Corp., Whitehouse Station, NJ, USA	PMH33	Janssen-Cilag s.r.o., Prague, Czech Republic
PIN77	GILEAD, ISTANBUL, Turkey	PMH34	Lundbeck SAS, Issy les Moulineaux, France
PIN78	None	PMH35	Janssen Cilag, Issy-Les-Moulineaux, France
PIN79	None	PMH36	None
PIN80	GILEAD, ISTANBUL, Turkey	PMH37	Eli Lilly, Windlesham, UK
PIN81	None	PMH38	Ferrer, Barcelona, Spain
PIN82	None	PMH39	None
PIN83	None	PMH40	None
PIN84	GSK, Marly Le Roi, France	PMH41	None
PIN85	ViiV Healthcare, Marly le Roi, France	PMH42	Janssen-Cilag NV, Beerse, Belgium
PIN86	Janssen EMEA, Beerse, Belgium	PMH43	Janssen-Cilag GmbH, Neuss, Germany
PIN87	Sanofi Pasteur, Lyon, France	PMH44	Bristol City Council, Bristol, UK
PIN88	ViiV Healthcare, Brentford, Middlesex, UK	PMH45	Shire Development LLC, Wayne, PA, USA
PIN89	University Malaya, Kuala Lumpur, Malaysia	PMH46	None
PIN90	Hutman Diagnostics AG, Basel, Switzerland	PMH47	None
PIN91	SPMSD, Lyon, France	PMH48	None
PIN92	Janssen Cilag, Neuss, Germany	PMH49	Lundbeck S.A.S., Issy-les-Moulineaux Cedex, UK
PIN93	Truven Health Analytics, Bethesda, MD, USA	PMH50	Lundbeck S.A.S., Issy-les-Moulineaux Cedex, France
PIN94	None	PMH51	Janssen-Cilag BV, Tilburg, The Netherlands
PIN95	None	PMH52	Lundbeck SAS, Issy-les-Moulineaux, France
PIN96	Janssen Pharmaceutica NV, Beerse, Belgium	PMH53	None
PIN97	None	PMH54	None
PIN98	None	PMH55	Health Services Executive, Cork, Ireland
PIN99	None	PMH56	Pfizer Japan Inc., Tokyo, Japan
PIN100	GlaxoSmithKline Biologicals S.A., Rixensart, Belgium	PMH57	Ferrer, Barcelona, Spain
PIN101	None	PMH58	Reckitt Benckiser, Richmond, VA, USA
PIN102	Janssen Research and Development, Beerse, Belgium	PMH59	None
PIN103	None	PMH60	Shire Development LLC, Wayne, PA, USA
PIN104	None	PMH61	None
PIN105	None	PMH62	None
PIN106	Bristol-Myers Squibb Pharmaceuticals Ltd., New York, NY, USA	PMH63	None
PIN107	None		
PIN108	Pfizer, New York, NY, USA		



REFERENCE CODE	FINANCIAL SUPPORT	REFERENCE CODE	FINANCIAL SUPPORT
PMH64	None	PMS71	Pfizer Deutschland GmbH, Berlin, Germany
PMH65	Pfizer, S.L.U., Madrid, Spain	PMS72	Amgen, Zug, Switzerland
PMH66	The research is funded by EU-ICT FP7-eHM, project-ID-287509, Brussels, Germany	PMS73	UCB Pharma, Brussels, Belgium
PMH67	Lundbeck SAS, Issy-les-Moulineaux, France	PMS74	Merck Sharpe & Dohme, Whitehouse Station, NJ, USA
PMH69	None	PMS75	Janssen Global Services, Titusville, NJ, USA; Janssen R&D, Raritan, NJ, USA
PMH70	KJT Group, Inc., Honeyoe Falls, NY, USA	PMS76	UCB Pharma, Brussels, Belgium
PMH71	Lundbeck SAS, Paris, France	PMS77	Janssen Global Services, Titusville, NJ, USA; Janssen Research and Development, Raritan, NJ, USA
PMH72	None	PMS78	AbbVie, Stockholm, Sweden
PMH73	None	PMS79	MSD, Athens, Greece
PMH74	None	PMS80	None
PMS1	Celgene Corporation, Warren, NJ, USA	PMS81	Pfizer Deutschland GmbH, Berlin, Germany
PMS2	Celgene Corporation, Warren, NJ, USA	PMS82	None
PMS3	Janssen Pharmaceutica N.V., Beerse, Belgium	PMS83	UCB Pharma, Brussels, Belgium
PMS4	None	PMS84	UCB Pharma, Brussels, Belgium
PMS5	None	PMS85	None
PMS6	Bristol Myers Squibb, Rome, Italy	PMS86	Double Helix Consulting, London, UK
PMS7	National Evidence-based Healthcare Collaborating Agency, Seoul, South Korea	PMS87	None
PMS8	Hanwha Chemical, Seoul, South Korea	PMS88	ICON Plc., London, UK
PMS9	None	PMS89	None
PMS10	Roche, Basel, Switzerland	PMS90	Plan de Calidad para el Sistema Nacional de Salud, Madrid, Spain
PMS11	National Science Council, Taipei, Taiwan; Pfizer Taiwan, Taipei, Taiwan	PMS91	None
PMS12	Bioventus LLC, Durham, NC, USA	PMS92	Amgen Bulgaria, Sofia, Bulgaria
PMS13	Janssen-Cilag GmbH, Neuss, Germany	PMS93	Amgen Switzerland AG, Zug, Switzerland
PMS14	Janssen Pharmaceutical, Athens, Greece	PMS94	Canadian Institute for Health Research (CIHR), Ottawa, ON, Canada; Canadian Arthritis Society, Toronto, ON, Canada
PMS15	UCB Pharma, Brussels, Belgium	PMS95	Merck, North Wales, PA, USA
PMS16	None	PMS96	AstraZeneca Canada Inc., Mississauga, ON, Canada
PMS17	Medtronic LLC, Moscow, Russia	PMS97	Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea
PMS18	Medtronic, Tolochenaz, Switzerland	PND1	EMD Serono, Rockland, MA, USA
PMS19	Celgene Corporation, Warren, NJ, USA	PND2	GSK, Brentford, UK
PMS20	Pfizer, Lisbon, Portugal	PND3	Abbvie, Madrid, Spain
PMS21	Medtronic International Trading Sàrl, Tolochenaz, Switzerland	PND4	Genzyme, A Sanofi Company, Cambridge, MA, USA
PMS22	MSD B.V., Haarlem, The Netherlands	PND5	None
PMS23	UCB Pharma, Brussels, Belgium	PND6	Ministry of Health and Welfare, Seoul, South Korea
PMS24	None	PND7	None
PMS25	UCB Pharma, Brussels, Belgium	PND8	Biogen Idec, Cambridge, MA, USA
PMS26	IPSEN Pharma, Boulogne-Billancourt, France	PND9	Medtronic, Minneapolis, MN, USA
PMS27	AMGEN Brazil, Sao Paulo, Brazil	PND10	Genzyme, a Sanofi company, Cambridge, MA, USA
PMS28	None	PND11	None
PMS29	None	PND12	Biogen Idec, Cambridge, MA, USA
PMS30	Novartis Pharmaceuticals UK Limited, Camberley, UK	PND13	EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, Rockland, MA, USA
PMS31	Novartis Pharmaceuticals UK Limited, Camberley, UK	PND14	None
PMS32	None	PND15	Biogen Idec, Cambridge, MA, USA
PMS33	Johnson and Johnson, New Brunswick, NJ, USA	PND16	Orion Corporation, Espoo, Finland
PMS34	None	PND17	Medtronic, Minneapolis, MN, USA
PMS35	Bristol-Myers Squibb, Princeton, NJ, USA	PND18	Novartis, Milan, Italy
PMS36	None	PND19	Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands
PMS37	None	PND20	Novartis Farma – Produtos Farmacêuticos S.A., Porto Salvo, Portugal
PMS38	UCB Pharma S.A., Brussels, Belgium	PND21	Medtronic, Tolochenaz, Switzerland
PMS39	None	PND22	Teva Pharma, Madrid, Spain
PMS40	Pfizer, S.L.U., Madrid, Spain	PND23	Biogen Idec, Cambridge, MA, USA
PMS41	NIHR HTA, Southampton, UK	PND24	NRF, Pretoria, South Africa
PMS42	Telecom Italia, Rome, Italy	PND25	UCB Pharma, Brussels, Belgium
PMS43	None	PND26	Ipsen Operations Russia, Moscow, Russia
PMS44	Intrinsic Therapeutics, Inc., Woburn, MA, USA	PND27	Medtronic International, Tolochenaz, Switzerland
PMS45	Roche, Moscow, Russia	PND28	None
PMS46	Pfizer, Lisbon, Portugal	PND29	Abbvie, Madrid, Spain
PMS47	Savient Pharma Ireland Limited, Dublin, Ireland	PND30	None
PMS48	National Evidence-based Healthcare Collaborating Agency, Seoul, South Korea	PND31	None
PMS49	Stryker, PUSIGNAN, France	PND32	None
PMS50	Ministry of Education, Culture, Sports, Science and Technology, Grant-in-Aid for Scientific Research (KAKENHI), Tokyo, Japan	PND33	Merck SA, Alges, Portugal
PMS51	None	PND34	Medtronic Ibérica, S.A., Madrid, Spain
PMS52	NIHR RFPB grant, Twickenham, UK	PND35	Avanir Pharmaceuticals, Inc., Aliso Viejo, CA, USA
PMS53	None	PND36	None
PMS54	UCB Pharma, Brussels, Belgium	PND37	Biogen Idec Slovak Republic Ltd., Bratislava, Slovak Republic
PMS55	Servier, Petaling Jaya, Malaysia	PND38	None
PMS56	Roche Products Limited, Welwyn Garden City, UK	PND39	Biogen Idec s.r.o., Prague, Czech Republic
PMS57	None	PND40	EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, Rockland, MA, USA
PMS58	Yrjö Jahnsson Foundation, Helsinki, Finland	PND41	EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, Rockland, MA, USA
PMS59	Bristol-Myers Squibb, Princeton, NJ, USA	PND42	UCB Pharma, Athens, Greece
PMS60	None	PND43	Merck SA, Alges, Portugal
PMS61	None	PND44	Boston Scientific, Milan, Italy
PMS62	Roche, Monza, Italy	PND45	EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, Rockland, MA, USA
PMS63	Amgen Inc., Thousand Oaks, CA, USA	PND46	French Ministry of Health, Paris, France
PMS64	Merck & Co., Inc., Whitehouse Station, NJ, USA	PND47	Biogen Idec, Weston, MA, USA
PMS65	Merck & Co., Inc., Whitehouse Station, NJ, USA	PND48	None
PMS66	None	PND49	Novartis Pharmaceuticals UK Ltd., Camberley, UK
PMS67	National Institute of Arthritis and Musculoskeletal and Skin Diseases, Houston, TX, USA	PND50	Alvogen Pharma doo Serbia, Belgrade, Serbia and Montenegro
PMS68	Merck & Co., Inc., Whitehouse Station, NJ, USA	PND51	None
PMS69	None		
PMS70	Janssen-Cilag Ltd., High Wycombe, UK		

REFERENCE CODE	FINANCIAL SUPPORT	REFERENCE CODE	FINANCIAL SUPPORT
PND52	Funding for analysis was provided by Genzyme, a Sanofi company, Helsinki, Finland	PRM50	Center for translational and molecular medicine, Eindhoven, The Netherlands
PND53	Medtronic Ibérica, S.A., Madrid, Spain	PRM51	Federal Ministry of Health, Berlin, Germany
PND54	None	PRM52	None
PND55	Biogen Idec, Ismaning, Germany	PRM53	ALLEGRIA onlus, Milano, Italy
PND56	EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, Rockland, MA, USA	PRM54	Bayer Healthcare Pharmaceuticals, Inc., Whippany, NJ, USA
PND57	Funding for analysis was provided by Genzyme, a Sanofi company, Helsinki, Finland	PRM55	Health Research Board, Dublin, Ireland
PND58	Novartis Pharma AG, Basel, Switzerland	PRM56	Truven Health Analytics, Ann Arbor, MI, USA
PND59	Novartis Pharma AG, Basel, Switzerland	PRM57	Sanofi-Aventis Hungaria, Budapest, Hungary
PND60	None	PRM58	Mapi Research Trust, Lyon, France
PND61	None	PRM59	Mapi Research Trust, Lyon, France
PND62	Biogen Idec, Cambridge, MA, USA	PRM60	None
PND63	Eisai Inc., Woodcliff Lake, NJ, USA	PRM61	IMS Health, London, UK; AstraZeneca, Manchester, UK
PND64	Biogen Idec, Cambridge, MA, USA	PRM62	PPD, Wilmington, NC, USA
PND65	Eisai, Inc., Woodcliff Lake, NJ, USA	PRM63	None
PND66	Novartis Farmacéutica, S.A., Barcelona, Spain	PRM64	None
PND67	Eli Lilly and Company, Indianapolis, IN, USA	PRM65	ZonMW, The Hague, The Netherlands
PND68	Lilly Deutschland GmbH, Bad Homburg, Germany	PRM66	GSK Biologicals SA, Wavre, Belgium
PND69	Eisai, Inc., Woodcliff Lake, NJ, USA	PRM67	None
PND70	Biogen Idec, Cambridge, MA, USA	PRM68	HealthCore, Wilmington, DE, USA
PND71	Novartis Farmacéutica, Barcelona, Spain	PRM69	None
PND72	Biogen Idec, Ismaning, Germany	PRM70	Truven Health Analytics, Bethesda, MD, USA
PND73	Genzyme, a Sanofi company, Cambridge, MA, USA	PRM71	None
PND74	UCB Pharma, Brussels, Belgium	PRM72	None
PND75	None	PRM73	None
PND76	None	PRM74	National Institute for Health Research, London, UK
PND77	None	PRM75	None
PND78	None	PRM76	None
PND79	None	PRM77	None
PND80	None	PRM78	None
PRM1	Eli Lilly and Company Ltd., Indianapolis, IN, USA	PRM79	The Netherlands Organization for Health Research and Development (ZonMW), The Hague, The Netherlands
PRM2	None	PRM80	Bristol Myers Squibb, Uxbridge, UK
PRM3	NIHR, Leeds, UK	PRM81	None
PRM4	Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA	PRM82	None
PRM5	ICON Clinical Research UK, Eastleigh, UK	PRM83	Eisai, Inc., Woodcliff Lake, NJ, USA
PRM6	None	PRM84	Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; Boehringer Ingelheim The Netherlands, Alkmaar, The Netherlands; GlaxoSmithKline, Middlesex, UK; Novartis, Basel, Switzerland; Takeda Pharmaceuticals, Glattpark-Opfikon, Switzerland
PRM7	None	PRM85	Novartis Pharma AG, Basel, Switzerland
PRM8	None	PRM86	Janssen-Cilag A/S, Birkerød, Denmark
PRM9	None	PRM87	None
PRM10	Mapi, Boston, MA, USA	PRM88	Amgen, Zug, Switzerland
PRM11	ICON PLC, Oxford, UK	PRM89	None
PRM12	Pfizer Ltd., Walton Oaks, UK	PRM90	Novartis Pharmaceuticals UK Limited, Frimley, UK
PRM13	Thai Traditional Medical Knowledge Fund, Department for Development of Thai Traditional and Alternative Medicine, Ministry of Public Health, Bangkok, Thailand	PRM91	Supported by the COMET Center ONCOTYROL, which is funded by the Austrian Federal Ministries BMVIT/BMWFJ (via FFG) and the Tiroler Zukunftsstiftung/Standortagentur Tirol (SAT), Innsbruck, Austria
PRM14	Mundipharma International Limited, Cambridge, UK	PRM92	Mundipharma International Limited, Cambridge, UK
PRM15	Janssen, High Wycombe, UK	PRM93	Genome Quebec, Montreal, QC, Canada
PRM16	AstraZeneca plc, Molndal, Sweden	PRM94	Oncotryol, Innsbruck, Austria
PRM17	None	PRM95	None
PRM18	Janssen Pharmaceutica NV, beerse, Belgium	PRM96	Innovative Medicine Initiative Joint Undertaking, Bern, Switzerland
PRM19	None	PRM97	3M Deutschland GmbH, Neuss, Germany
PRM20	None	PRM98	None
PRM21	IRD, Marseille, France	PRM99	None
PRM22	None	PRM100	GSK, Research Triangle Park, NC, USA
PRM23	None	PRM101	None
PRM24	2Actelion Pharmaceuticals US, Inc., San Francisco, CA, USA	PRM102	None
PRM25	None	PRM103	Genome Quebec, Montreal, QC, Canada
PRM26	Medical Research Council, London, UK; Cancer Research UK, London, UK; UK Department of Health, London, UK	PRM104	GlaxoSmithKline, Wavre, Belgium
PRM27	Medical Research Council (Network of Hubs for Trials Methodology Research Network Grant ref: R35), London, UK; The National Institute for Health Research (NIHR) (Programme Grant for Applied Research (RP-PG-0407-10070))., London, UK	PRM105	CTTM, Eindhoven, The Netherlands
PRM28	Novartis Pharmaceuticals UK Ltd., Camberley, UK	PRM106	Novartis Pharma AG, Basel, Switzerland
PRM29	None	PRM107	Boehringer Ingelheim, Ingelheim am Rhein, Germany
PRM30	AbbVie, Chicago, IL, USA	PRM108	ViroPharma, Maidenhead, UK
PRM31	None	PRM109	Austrian Research Promotion Agency (FFG), Vienna, Austria
PRM32	None	PRM110	GlaxoSmithKline, Bithoven, The Netherlands
PRM33	None	PRM111	Sanofi, Guildford, UK
PRM34	None	PRM112	None
PRM35	GILEAD, London, UK	PRM113	Navigant Consulting, London, UK
PRM36	None	PRM114	National Institute of Health Research (NIHR), London, UK
PRM37	Bristol Myers Squibb, Uxbridge, UK	PRM115	GlaxoSmithKline, Collegeville, PA, USA
PRM38	Universidad Nacional de Colombia, Bogota, Colombia	PRM116	Decision Resources, LLC, Burlington, MA, USA
PRM39	None	PRM117	3M Deutschland GmbH, Neuss, Germany
PRM40	None	PRM118	Otsuka Pharmaceutical Europe Ltd., Wexham, UK
PRM41	None	PRM119	Decision Resources Group, Burlington, MA, USA
PRM42	None	PRM120	F. Hofmann – La Roche AG, Basel, Switzerland
PRM43	None	PRM121	RTI-HS, Manchester, UK
PRM44	Eli Lilly, Indianapolis, IN, USA	PRM122	Evidera, San Francisco, CA, USA
PRM45	None	PRM123	Costello Medical Consulting Ltd., Cambridge, UK
PRM46	None	PRM124	AstraZeneca, Gaithersburg, MD, USA
PRM47	Novartis Pharma AG, Basel, Switzerland	PRM125	Les Entreprises du Médicament (LEEM), Paris, France
PRM48	None	PRM126	None
		PRM127	None
		PRM128	None

REFERENCE CODE	FINANCIAL SUPPORT	REFERENCE CODE	FINANCIAL SUPPORT
PRM129	RTI Health Solutions, Research Triangle Park, NC, USA	PRM212	None
PRM130	None	PRM214	Celgene Corporation, Summit, NJ, USA
PRM131	Pharmerit, Rotterdam, The Netherlands	PRM215	None
PRM132	UICC, Geneva, Switzerland	PRM216	None
PRM133	Agility Global Health Solutions (AGHS), Centurion, South Africa	PRM217	None
PRM134	None	PRM218	None
PRM135	None	PRM219	GlaxoSmithKline, Uxbridge, UK
PRM136	None	PRM220	None
PRM137	Basilea Pharmaceuticals, München, Germany; Glaxo Smith Kline, München, Germany	PRM221	Almirall, Uxbridge, UK
PRM138	Medivation, Inc., San Francisco, CA, USA; Astellas Pharma Global Development, Inc., Northbrook, IL, USA	PRM222	None
PRM139	RIVM, Bilthoven, The Netherlands	PRM223	GlaxoSmithKline, Wavre, Belgium
PRM140	Ministry of Health, Malaysia, Malaysia	PRM224	None
PRM141	None	PRM225	None
PRM142	None	PRM226	None
PRM143	DePuy Orthopaedics, Inc., Warsaw, IN, USA	PRM227	MAPI, Lyon, France
PRM144	UCB Pharma, Brussels, Belgium	PRM228	None
PRM145	Actelion Pharmaceuticals Ltd., Allschwil, Switzerland	PRM229	The Netherlands Organization for Scientific Research, The Hague, The Netherlands
PRM146	Regeneron Pharmaceuticals, Tarrytown, NY, USA	PRM230	Evidera, Bethesda, MD, USA
PRM147	Ontario Institute for Cancer Research and Cancer Care Ontario, Toronto, ON, Canada; Canadian Centre for Applied Research in Cancer Control, Toronto, ON, Canada	PRM231	None
PRM148	Bristol Myers Squibb, Uxbridge, UK	PRM232	None
PRM149	RTI-Health Solutions, Research Triangle Park, NC, USA	PRM233	None
PRM150	None	PRM234	None
PRM151	UCB Pharma, Brussels, Belgium	PRM235	National Institute for Health Research, London, UK
PRM152	Amgen (Europe) GmbH, Zug, Switzerland	PRM236	None
PRM153	EuroQol Group, Rotterdam, The Netherlands	PRM237	None
PRM154	EuroQol Group Foundation, Rotterdam, The Netherlands	PRM238	None
PRM155	AbbVie, Campoverde di Aprilia (LT), Italy	PRM239	Bridge Medical, London, UK
PRM156	RTI-HS, RTP, NC, USA	PRM240	NIHR Evaluation, Trials and Studies, Southampton, UK
PRM157	The EuroQol Group, Rotterdam, The Netherlands	PRM241	Eli Lilly Regional Operations GmbH, Vienna, Austria
PRM158	Mapi, Lyon, France	PRM242	None
PRM159	AstraZeneca Ltd., Macclesfield, England	PRM243	None
PRM160	None	PRM244	Eli Lilly Regional Operations GmbH, Vienna, Austria
PRM161	Pfizer Ltd., Tadworth, UK	PRM245	Novo Nordisk, Bagsværd, Denmark
PRM162	EuroQol Group, Rotterdam, The Netherlands	PRM246	None
PRM163	None	PRM247	IMI, Brussels, Belgium
PRM164	None	PRM248	Quintiles, Reading, UK
PRM165	None	PRM249	Santen, Inc., Emeryville, CA, USA
PRM166	None	PRM250	Novartis, Moscow, Russia
PRM167	None	PRM251	Eli Lilly Regional Operations GmbH, Vienna, Austria
PRM168	None	PRM252	None
PRM169	Abacus International, Bicester, UK	PRM253	Onyx Pharmaceuticals, Inc., San Francisco, CA, USA
PRM170	None	PRM254	Amaris, London, UK
PRM171	None	PRM255	Axonal, Paris, France
PRM172	None	PRM256	MoH Brazil, Brasilia, Brazil
PRM173	None	PRS1	Thermo Fisher Scientific, Uppsala, Sweden
PRM174	None	PRS2	MSD France, Courbevoie, France
PRM175	None	PRS3	Novartis, Istanbul, Turkey
PRM176	None	PRS4	Basilea Pharmaceutica Ltd., Basel, Switzerland
PRM177	None	PRS5	GlaxoSmithKline Inc., RTP, NC, USA
PRM178	None	PRS6	Novartis, Basel, Switzerland
PRM179	Bayer Yakuhin Ltd., Tokyo, Japan	PRS7	Novartis, East Hannover, NJ, USA
PRM180	PAR Inc., Lutz, FL, USA	PRS8	None
PRM181	Lumena, San Diego, CA, USA	PRS9	None
PRM182	Nestle Health Science, Barcelona, Spain	PRS10	None
PRM183	German Federal Ministry of Education and Research, Berlin, Germany	PRS11	Takeda Development Centre Europe Ltd., London, UK
PRM184	Eisai Inc., Woodcliff Lake, NJ, USA	PRS12	Takeda Development Centre Europe, London, UK
PRM186	None	PRS13	NA, CA, USA
PRM187	None	PRS14	Takeda Pharmaceuticals International, London, UK
PRM188	IMI, Brussels, Belgium	PRS15	None
PRM189	Creativ-ceutical, London, UK	PRS16	None
PRM190	Abacus International, Bicester, UK	PRS17	GSK, Uxbridge, UK
PRM191	Creativ-ceutical, London, UK	PRS18	GSK, Uxbridge, UK
PRM192	GlaxoSmithKline, Philadelphia, PA, USA	PRS19	Teva Pharmaceuticals Europe B.V, Amsterdam, The Netherlands
PRM193	Lunbeck, Issy-les-Moulineaux, France	PRS20	Novartis Farma – Produtos Farmacêuticos S.A., Porto Salvo, Portugal
PRM194	F. Hoffmann-La Roche, Basel, Switzerland	PRS21	Boehringer Ingelheim, Bracknell, UK
PRM195	Leicester University, Leicester, UK	PRS22	Pfizer, Inc., São Paulo, Brazil
PRM196	None	PRS23	GlaxoSmithKline d.o.o., družba za promet s farmacevtskimi izdelki, Ljubljana, Slovenia, Ljubljana, Slovenia
PRM197	None	PRS24	GlaxoSmithKline d.o.o., družba za promet s farmacevtskimi izdelki, Ljubljana, Slovenia, Ljubljana, Slovenia
PRM198	Eli Lilly Regional Operations Ges.m.b.H., Vienna, Austria	PRS25	ResMed Germany Inc., Martinsried, Germany
PRM199	None	PRS26	Biogen Idec, Cambridge, MA, USA
PRM200	Agence Nationale de Sécurité des Médicaments, Sain-Denis, France	PRS27	None
PRM201	None	PRS28	Glaxosmithkline, Ystambul, Turkey
PRM202	NIHR, Leeds, UK	PRS29	Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
PRM203	Takeda Pharmaceuticals International GmbH, Zurich, Switzerland	PRS30	Pfizer, New York, NY, USA
PRM204	Health Research Board, Dublin, Ireland	PRS31	Novartis Korea, Seoul, South Korea
PRM205	None	PRS32	Glaxosmithkline, Ystambul, Turkey
PRM206	Shire Development LLC, Wayne, PA, USA	PRS33	None
PRM207	None	PRS34	Ministry for Health, Welfare & Family Affairs, Seoul, South Korea
PRM208	Ministry of Health of the Czech Republic, Prague, Czech Republic	PRS35	None
PRM210	None	PRS36	None
PRM211	EveryLife Foundation for Rare Diseases, Novato, CA, USA	PRS37	IMU, KL, Malaysia
		PRS38	IMU, KL, Malaysia
		PRS39	None
		PRS40	None

REFERENCE CODE	FINANCIAL SUPPORT	REFERENCE CODE	FINANCIAL SUPPORT
PRS41	GlaxoSmithKline S.R.L., Bucharest, Romania	PSS30	Beijing Novartis Pharma Ltd., Beijing, China
PRS42	Stichting Achmea Gezondheidszorg, Zeist, The Netherlands;	PSS31	Beijing Novartis Pharma Ltd., Beijing, China
	The Netherlands Organisation for Health Research and	PSS32	NIHR HTA 12/71, Southampton, UK; NIHR HTA 12/71,
	Development (Zon-MW), Den Haag, The Netherlands		Southampton, UK
PRS43	Janssen Pharmaceutica NV, Beerse, Belgium	PSS33	LEO Pharma Oy, Vantaa, Finland
PRS44	GlaxoSmithKline Inc., RTP, NC, USA	PSS34	Novartis, Basel AG, Switzerland
PRS45	GlaxoSmithKline, Uxbridge, UK	PSS35	None
PRS46	None	PSS36	Cochlear AG, Basel, Switzerland
PRS47	Glenmark, Moscow, Russia	PSS37	None
PRS48	Novartis Farmacéutica, Mexico, Mexico	PSS38	Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea
PRS49	None	PSS39	NIHR, London, UK
PRS50	Simpex Pharma, Moscow, Russia	PSS40	Novartis AG, Basel, Switzerland
PRS51	Novartis, Barcelona, Spain	PSS41	Leo Pharma Sweden, Malmö, Sweden
PRS52	Stallergenes, Antony, France	PSS42	Novartis Pharma AG, Basel, Switzerland
PRS53	Nestle Rossiya LLC, Moscow, Russia	PSS43	Riemser Pharma GmbH, Greifswald - Insel Riems, Germany
PRS54	None	PSS44	None
PRS55	ZonMW, The Hague, The Netherlands	PSS45	None
PRS56	Stallergenes, Antony, France	PSS46	Novartis Farmaceutica, Barcelona, Spain
PRS57	Novartis, Hellas SA, Greece	PSS47	None
PRS58	Novartis Pharmaceuticals, Barcelona, Spain	PSS48	Bayer Pharma AG, Berlin, Germany
PRS59	Stallergenes, Antony, France	PSS49	None
PRS60	Pulmonx, Inc., Redwood City, CA, USA	PSS50	None
PRS61	Meda Pharmaceuticals, Inc., Somerset, NJ, USA	PSS51	Novartis Farmaceutica S.A., Barcelona, Spain
PRS62	Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands	PSS52	National Health and Medical Research Council, Canberra,
PRS63	Novartis, East Hannover, NJ, USA		Australia
PRS64	Mundipharma International Ltd., Cambridge, UK	PSS53	None
PRS65	MERCK S.L., Madrid, Spain	PSS54	Quintiles, Durham, NC, USA
PRS66	Meda Pharmaceuticals, Somerset, NJ, USA	PSS55	None
PRS67	Ministerio de Sanidad, Madrid, Spain	PSS56	None
PRS68	Consejería de Salud Junta de Andalucía, Sevilla, Spain	PSS57	None
PRS69	TEVA, Amsterdam, The Netherlands	PSS58	None
PRS70	Boehringer Ingelheim, Ingelheim, Germany	PSS59	None
PRS71	Almirall, S.A., Barcelona, Spain	PSY1	None
PRS72	EXACT-PRO Initiative, Bethesda, MD, USA	PSY2	Roche Pharma, Madrid, Spain
PRS73	Forest Research Institute, Inc., Jersey City, NJ, USA;	PSY3	AbbVie Canada, St-Laurent, QC, Canada
	Almirall, S.A., Barcelona, Spain	PSY4	UCB Pharma, Brussels, Belgium
PRS74	Biogen Idec, Cambridge, MA, USA	PSY5	None
PRS75	None	PSY6	F. Hoffmann-La Roche, Basel, Switzerland
PRS76	None	PSY7	None
PRS77	CHIESI España SA, Malaga, Spain	PSY8	Productos Medix SA de CV, Mexico City, Mexico
PRS78	None	PSY9	Pfizer México SA de CV, Ciudad de México, Mexico
PRS79	ALK-Abelló A/S, Hørsholm, Denmark	PSY10	None
PRS80	None	PSY11	None
PRS81	GlaxoSmithKline, Uxbridge, UK	PSY12	Novartis Farma – Produtos Farmacêuticos S.A., Lisbon, Portugal
PRS82	Novartis Hellas, Metamorfosi, Attica, Greece	PSY13	None
PRS83	None	PSY14	None
PRS84	Boehringer Ingelheim, Prague, Czech Republic	PSY15	Janssen-Cilag GmbH, Neuss, Germany
PRS85	Center for Clinical and Translational Science, Burlington, VT, USA	PSY16	MSD France, Courbevoie, France
PRS86	None	PSY17	MSD France, Courbevoie, France
PRS87	GlaxoSmithKline, Madrid, Spain	PSY18	None
PRS88	None	PSY20	Covidien, Arnold, MO, USA
PRS89	Pfizer Japan, Tokyo, Japan	PSY21	None
PR1	National Institute of Public Health and the Environment, Bilthoven,	PSY22	BioMarin, Dublin, Ireland; Alexion, Cheshire, CT, CT, USA
	The Netherlands	PSY24	The Netherlands Organization for Health Research and
PR2	Janssen-Cilag Ltd., High Wycombe, UK		Development, the Hague, The Netherlands
PR3	None	PSY25	Mundipharma International, Cambridge, UK
PR4	The EuroQol Group, Rotterdam, The Netherlands	PSY26	None
PSS1	Novartis Pharma AG, Basel, Switzerland	PSY27	None
PSS2	Tissue Therapies Ltd., Brisbane, Australia	PSY28	Astellas Pharma, Madrid, Spain
PSS3	Novartis, Istanbul, Turkey	PSY29	None
PSS4	Novartis, Hellas SA, Greece	PSY30	NRF, Pretoria, South Africa
PSS5	Mölnlycke Health Care Kft, Budapest, Hungary	PSY31	Novartis Hellas SA, Metamorfosis, Greece
PSS6	None	PSY32	Takeda Farmacéutica España, Madrid, Spain
PSS7	None	PSY33	None
PSS8	Smith & Nephew Biotherapeutics, Fort Worth, TX, USA	PSY34	NRF, Pretoria, South Africa
PSS9	None	PSY35	Purdue Pharma, Stamford, CT, USA
PSS10	The Medicines Company, Parsippany, NJ, USA	PSY36	Novartis, East Hanover, NJ, USA
PSS12	Singapore Eye Research Institute, Singapore, Singapore	PSY37	Purdue Pharma, Stamford, CT, USA
PSS13	Dutch Burn Foundation, Beverwijk, The Netherlands	PSY38	Novartis, East Hanover, NJ, USA
PSS14	Novartis Farmaceutica S.A., Barcelona, Spain	PSY39	None
PSS15	Novartis Farmaceutica, Barcelona, Spain	PSY40	None
PSS16	Novartis, Istanbul, Turkey	PSY41	None
PSS17	Novartis Hellas, Athens, Greece	PSY42	Novartis Hellas, Athens, Greece
PSS18	None	PSY43	None
PSS19	Novartis Ireland, Dublin, Ireland	PSY44	None
PSS20	None	PSY45	UCB Pharma, Brussels, Belgium
PSS21	The Ministry of Science and Education of the Republic of Serbia,	PSY46	GlaxoSmithKline, Halandri, Greece; GlaxoSmithKline, Brentford, UK
	Grant N°175014, Belgrade, Serbia and Montenegro	PSY47	AMGEN BRAZIL, São Paulo, Brazil
PSS22	Janssen, Panama, Panama	PSY48	Eisai, Inc., Woodcliff Lake, NJ, USA
PSS23	Novartis Farmacéutica, Mexico, Mexico	PSY49	Otsuka Pharmaceutical Development & Commercialization,
PSS24	Pfizer s.r.o., New York City, NY, USA		Princeton, NJ, USA
PSS25	Novartis Pharma AG, Basel, Switzerland	PSY50	Otsuka Pharmaceutical Development & Commercialization,
PSS26	Bayer AB, Solna, Sweden		Princeton, NJ, USA
PSS27	Dutch Burns Foundation, Beverwijk, The Netherlands; Fonds	PSY51	LFB - Laboratoire Francais Du Fractionnement Et Des
	NutsOhra, Amsterdam, The Netherlands		Biotechnologies, Les Ulis, Courtaboeur, France
PSS28	None	PSY52	None
PSS29	Pfizer, New York City, NY, USA	PSY53	GSK, Tres Cantos (Madrid), Spain

**REFERENCE  
CODE**
**FINANCIAL SUPPORT**

PSY54	Roche Farmacêutica Química, Lda., Amadora, Portugal
PSY55	National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care for South Yorkshire (NIHR CLAHRC SY), Sheffield, UK
PSY56	Astellas Pharma Europe Ltd., Chertsey, UK
PSY57	Bayer, Mijdrecht, The Netherlands
PSY58	Grünenthal, Aachen, Germany
PSY59	Productos Medix SA de CV, Mexico City, Mexico
PSY60	Psicofarma, Mexico City, Mexico
PSY61	None
PSY62	GSK Spain, Tres Cantos - Madrid, Spain
PSY63	Amgen Biofarmacêutica, Oeiras, Portugal
PSY64	GlaxoSmithKline, Halandri, Greece
PSY65	Pfizer Portugal, Porto Salvo, Portugal
PSY66	Amgen s.r.o., Prague, Czech Republic
PSY67	Pfizer Japan Inc., Tokyo, Japan
PSY68	None
PSY69	Baxter Slovakia s.r.o., Bratislava, Slovak Republic
PSY70	Psicofarma, Mexico City, Mexico
PSY71	None
PSY72	None
PSY73	GSK, Tres Cantos (Madrid), Spain
PSY74	Celgene, Summit, NJ, USA
PSY75	None
PSY76	Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
PSY77	Vertex Pharmaceuticals Incorporated, Boston, MA, USA
PSY78	Eisai, Inc., Woodcliff Lake, NJ, USA
PSY79	Janssen Research & Development, Spring House, PA, USA
PSY80	Bayer Pharma, Berlin, Germany
PSY81	Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea
PSY82	Forest Research Institute, Jersey City, NJ, USA
PSY83	Forest Research Institute, Jersey City, NJ, USA
PSY84	Mapi, Lyon, France
PSY85	None
PSY86	None
PSY87	Merck, Sharp & Dohme, Madrid, Spain
PSY88	Merck, Sharp & Dohme, Madrid, Spain
PSY89	F. Hoffmann-La Roche Ltd., Basel, Switzerland
PSY90	Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA
PSY91	Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea
PSY92	None
PSY93	None
PSY94	European Union Health Programme [grant A101205], Brussels, Belgium
PSY95	Arthritis Research UK charity, Chesterfield, UK
PSY96	Italian Ministry of Public Education, Roma, Italy
PSY97	None
PSY98	None
PSY99	None
PSY100	None
PSY101	None
PSY102	None
PSY103	None
PSY104	None
PSY105	None
PSY106	European Commission, Brussels, Belgium

**REFERENCE  
CODE**
**FINANCIAL SUPPORT**

PSY107	European Commission, Brussels, Belgium
PSY108	None
PSY109	None
PSY110	Actellion Hellas S.A., Marousi, Athens, Greece
PSY111	Astrazeneca, Wilmington, DE, USA
PSY112	United Therapeutics, Research Triangle Park, NC, USA
PSY113	None
PSY114	Novartis Pharma B.V., Arnhem, The Netherlands
PSY115	None
PSY117	None
PSY118	None
PSY119	None
PSY120	None
PSY121	Faculty of Medicine, Nis, Yugoslavia
PUK1	Astellas Pharma Europe Ltd., Chertsey, UK
PUK2	National Science Council, Taipei, Taiwan; Taipei Wan Fang Hospital, Taipei, Taiwan
PUK3	None
PUK4	Universiti Teknologi Mara, Selangor, Maldives
PUK5	None
PUK6	Roche, Moscow, Russia
PUK7	Fresenius Kabi, Moscow, Russia
PUK8	Allergan Holdings Ltd., Marlow, UK
PUK10	None
PUK11	Health Research Board, Dublin, Ireland
PUK12	Eli Lilly and Company, Indianapolis, IN, USA
PUK13	NIHR, London, UK
PUK14	Wellspect HealthCare, Göteborg, Sweden
PUK15	Amgen Hellas, Athens, Greece
PUK16	Astellas Pharma Europe Ltd., Chertsey, UK
PUK17	Astellas Pharma Canada Inc., Markham, ON, Canada
PUK18	None
PUK19	None
PUK20	Novartis Farmacêutica, Mexico, Mexico
PUK21	Allergan Holdings Ltd., Marlow, UK
PUK22	Allergan Holdings Ltd., Marlow, UK
PUK23	Fresenius Kabi Asia Pacific Limited, Hong Kong, Hong Kong
PUK24	None
PUK25	Sanofi, Barcelona, Spain
PUK26	Allergan, Marlow, UK
PUK27	Astellas Pharma France, Levallois Perret, France
PUK28	Astellas Pharma Canada, Inc., Markham, ON, Canada
PUK29	None
PUK30	None
PUK31	None
PUK32	Astellas Pharma Europe Ltd., Chertsey, UK
PUK33	CSIC, Montevideo, Uruguay
PUK34	Astellas Pharma Europe Ltd., Chertsey, UK
PUK35	None
QA1	Costello Medical Consulting Ltd., Cambridge, UK
QA2	MRC, London, UK
QA3	Lilly S.A., Madrid, Spain
QA4	None
QL1	Eli Lilly and Company, Windlesham, Surrey, UK
QL2	None
QL3	Belgian Stroke Council, Hasselt, Belgium
QL4	County Council of Östergötland, Linköping, Sweden